Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)

Vivozon Pharmaceutical Revenue

Vivozon Pharmaceutical had revenue of 13.28B KRW in the quarter ending June 30, 2026, a decrease of -25.39%. This brings the company's total for the last twelve months to 50.34B, down -39.54% year-over-year. In the year 2025, Vivozon Pharmaceutical had annual revenue of 59.34B, down -32.26%. That makes Vivozon Pharmaceutical the 29,849th largest company in the world by revenue and 1,865th in South Korea.

• Revenue (ttm): 50.34B
• Revenue Growth: -39.54%
• P/S Ratio: 3.47
• Revenue / Employee: 286.05M
• Employees: 176
• Market Cap: 174.48B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Korea 55.94B 94.3%
• Other 2.01B 3.4%
• People's Republic of China 711.49M 1.2%
• Japan 346.21M 0.6%
• Russia 342.53M 0.6%

Fiscal year ended Dec 31, 2025 See the full Vivozon Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	59.34B	-28.26B	-32.26%
Dec 31, 2024	87.60B	16.28B	22.83%
Dec 31, 2023	71.32B	19.75B	38.31%
Dec 31, 2022	51.56B	-6.00B	-10.42%
Dec 31, 2021	57.56B	13.97B	32.04%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error